Cargando…

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

BACKGROUND: The multi-arm multi-stage (MAMS) trial is a new paradigm for conducting randomised controlled trials that allows the simultaneous assessment of a number of research treatments against a single control arm. MAMS trials provide earlier answers and are potentially more cost-effective than a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sydes, Matthew R, Parmar, Mahesh KB, James, Nicholas D, Clarke, Noel W, Dearnaley, David P, Mason, Malcolm D, Morgan, Rachel C, Sanders, Karen, Royston, Patrick
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704188/ https://www.ncbi.nlm.nih.gov/pubmed/19519885 http://dx.doi.org/10.1186/1745-6215-10-39

Ejemplares similares

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2011)

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2012)

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
por: Gilson, C., et al.
Publicado: (2017)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

The need for a cultural shift from two-arm to multi-arm RCTS
por: Sydes, Matthew R, et al.
Publicado: (2013)

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2012)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings
por: Noor, Nurulamin M., et al.
Publicado: (2020)

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis
por: Bratton, Daniel J, et al.
Publicado: (2013)

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
por: Sydes, M R, et al.
Publicado: (2018)

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
por: Ali, Adnan, et al.
Publicado: (2020)

How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design – a reanalysis of 4 trials
por: Barthel, FM-S, et al.
Publicado: (2009)

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial
por: Choodari-Oskooei, Babak, et al.
Publicado: (2023)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials
por: Noor, Nurulamin M, et al.
Publicado: (2022)

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
por: James, Nicholas D, et al.
Publicado: (2022)

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer
por: Zeissler, Marie-Louise, et al.
Publicado: (2020)

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
por: Parker, Christopher C, et al.
Publicado: (2018)

Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework
por: Blenkinsop, Alexandra, et al.
Publicado: (2019)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
por: Parker, Chris C., et al.
Publicado: (2022)

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
por: Royston, Patrick, et al.
Publicado: (2014)

Adding new experimental arms to randomised clinical trials: Impact on error rates
por: Choodari-Oskooei, Babak, et al.
Publicado: (2020)

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
por: Kass-Iliyya, Antoine, et al.
Publicado: (2018)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
por: Royston, Patrick, et al.
Publicado: (2013)

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
por: Clarke, Caroline S., et al.
Publicado: (2022)

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated
por: Royston, Patrick, et al.
Publicado: (2016)

Accuracy and Reproducibility of Conformal Radiotherapy using Data from a Randomised Controlled Trial of Conformal Radiotherapy in Prostate Cancer (MRC RT01, ISRCTN47772397)
por: Stanley, S., et al.
Publicado: (2008)

Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes
por: Bratton, Daniel J., et al.
Publicado: (2016)

A multi-arm multi-stage design for binary outcomes and application to tuberculosis
por: Bratton, Daniel, et al.
Publicado: (2013)

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
por: Clarke, N W, et al.
Publicado: (2019)

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
por: James, Nicholas D., et al.
Publicado: (2022)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
por: James, Nicholas D, et al.
Publicado: (2016)

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer
por: South, Annabelle, et al.
Publicado: (2016)

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
por: Foltynie, Tom, et al.
Publicado: (2023)

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
por: Langley, Ruth E, et al.
Publicado: (2013)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
por: Attard, Gerhardt, et al.
Publicado: (2022)

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
por: Royston, Patrick, et al.
Publicado: (2011)

Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis
por: Li, Vivien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_afmsjebdj4bjvctnika5pe386a